Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28974278 | 0.98 | ALDH1A1 (0.63) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL1134288 | 0.85 | PNMT (0.58) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL15156645 | 0.83 | NISCH (0.48) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL12261509 | 0.83 | NISCH (0.48) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL2675395 | 0.83 | NISCH (0.48) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL14862312 | 0.82 | NISCH (0.47) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL15476926 | 0.82 | NISCH (0.47) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL11661559 | 0.82 | PNMT (0.59) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL15476691 | 0.82 | NISCH (0.47) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL29669062 | 0.82 | NISCH (0.47) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4321647-A | — | — | None | — | — | JP | disclosed |
| CN-115867535-B | Substituted benzamides as modulators of TREX1 | 星座制药公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-4157821-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | Constellation Pharmaceuticals, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-115867535-A | Substituted benzamides as modulators of TREX1 | 星座制药公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2021243001-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021243001-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-8486985-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486985-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110136884-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136884-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| JP-H04321647-A | DICHLOROPHENYLPROPYLAMINE AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE | MITSUBISHI GAS CHEM CO INC | 1992-11-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | TREH, BRIX1, GBA1 | PNMT 2877/4885CYP1A2 692/4885CYP3A4 1058/4885 |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PNMT 2723/4885CYP1A2 131/4885CYP3A4 25/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | PNMT 2146/4885CYP1A2 313/4885CYP3A4 62/4885 |
| US-20110136884-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | PNMT 195/4885CYP1A2 224/4885CYP3A4 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.